Your browser doesn't support javascript.
Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.
DeSilva, Malini B; Mitchell, Patrick K; Klein, Nicola P; Dixon, Brian E; Tenforde, Mark W; Thompson, Mark G; Naleway, Allison L; Grannis, Shaun J; Ong, Toan C; Natarajan, Karthik; Reese, Sarah E; Zerbo, Ousseny; Kharbanda, Anupam B; Patel, Palak; Stenehjem, Edward; Raiyani, Chandni; Irving, Stephanie A; Fadel, William F; Rao, Suchitra; Han, Jungmi; Reynolds, Sue; Davis, Jonathan M; Lewis, Ned; McEvoy, Charlene; Dickerson, Monica; Dascomb, Kristin; Valvi, Nimish R; Barron, Michelle A; Goddard, Kristin; Vazquez-Benitez, Gabriela; Grisel, Nancy; Mamawala, Mufaddal; Embi, Peter J; Fireman, Bruce; Essien, Inih J; Griggs, Eric P; Arndorfer, Julie; Gaglani, Manjusha.
  • DeSilva MB; HealthPartners Institute, Minneapolis, Minnesota, United States.
  • Mitchell PK; Westat, Rockville, Maryland, United States.
  • Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, United States.
  • Dixon BE; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States.
  • Tenforde MW; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, United States.
  • Thompson MG; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, United States.
  • Naleway AL; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, United States.
  • Grannis SJ; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, United States.
  • Ong TC; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States.
  • Natarajan K; School of Medicine, Indiana University, Indianapolis, Indiana, United States.
  • Reese SE; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.
  • Zerbo O; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York , New York.
  • Kharbanda AB; New York Presbyterian Hospital, New York, New York, United States.
  • Patel P; Westat, Rockville, Maryland, United States.
  • Stenehjem E; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, United States.
  • Raiyani C; Children's Minnesota, Minneapolis, Minnesota, United States.
  • Irving SA; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, United States.
  • Fadel WF; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, United States.
  • Rao S; Baylor Scott & White Health, Temple, Texas, United States.
  • Han J; Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, United States.
  • Reynolds S; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States.
  • Davis JM; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana, United States.
  • Lewis N; School of Medicine, Indiana University, Indianapolis, Indiana, United States.
  • McEvoy C; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York , New York.
  • Dickerson M; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, United States.
  • Dascomb K; Westat, Rockville, Maryland, United States.
  • Valvi NR; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, United States.
  • Barron MA; HealthPartners Institute, Minneapolis, Minnesota, United States.
  • Goddard K; Centers for Disease Control and Prevention COVID-19 Response Team, Atlanta, Georgia, United States.
  • Vazquez-Benitez G; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, United States.
  • Grisel N; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States.
  • Mamawala M; School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.
  • Embi PJ; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, United States.
  • Fireman B; HealthPartners Institute, Minneapolis, Minnesota, United States.
  • Essien IJ; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah, United States.
  • Griggs EP; Baylor Scott & White Health, Temple, Texas, United States.
  • Arndorfer J; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, United States.
  • Gaglani M; Vanderbilt University Medical Center, Nashville, Tennessee, United States.
J Infect Dis ; 2022 Nov 23.
Article in English | MEDLINE | ID: covidwho-2294187
ABSTRACT

BACKGROUND:

We assessed COVID-19 vaccination impact on illness severity among adults hospitalized with COVID-19 August 2021-March 2022.

METHODS:

We evaluated differences in intensive care unit (ICU) admission, in-hospital death, and length of stay among vaccinated (2 or 3 mRNA vaccine doses) versus unvaccinated patients aged ≥18 years hospitalized for ≥24 hours with COVID-19-like illness (CLI) and positive SARS-CoV-2 molecular testing. We calculated odds ratios for ICU admission and death and subdistribution hazard ratios (SHR) for time to hospital discharge adjusted for age, geographic region, calendar time, and local virus circulation.

RESULTS:

We included 27,149 SARS-CoV-2 positive hospitalizations. During both Delta and Omicron-predominant periods, protection against ICU admission was strongest among 3-dose vaccinees compared with unvaccinated patients (Delta OR [CI] 0.52 [0.28-0.96]); Omicron OR [CI] 0.69 [0.54-0.87]). During both periods, risk of in-hospital of death was lower among vaccinated compared with unvaccinated but ORs were overlapping; during Omicron, lowest among 3-dose vaccinees (OR [CI] 0.39 [0.28-0.54]). We observed SHR >1 across all vaccination strata in both periods indicating faster discharge for vaccinated patients.

CONCLUSIONS:

COVID-19 vaccination was associated with lower rates of ICU admission and in-hospital death in both Delta and Omicron periods compared with being unvaccinated.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Infdis